CN114164149B - Lactobacillus plantarum P101 for relieving obesity and lead toxicity and application thereof - Google Patents
Lactobacillus plantarum P101 for relieving obesity and lead toxicity and application thereof Download PDFInfo
- Publication number
- CN114164149B CN114164149B CN202111431645.7A CN202111431645A CN114164149B CN 114164149 B CN114164149 B CN 114164149B CN 202111431645 A CN202111431645 A CN 202111431645A CN 114164149 B CN114164149 B CN 114164149B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- lead
- application
- obesity
- relieving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 51
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 51
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 51
- 208000008589 Obesity Diseases 0.000 title claims abstract description 21
- 235000020824 obesity Nutrition 0.000 title claims abstract description 21
- 231100000419 toxicity Toxicity 0.000 title abstract description 11
- 230000001988 toxicity Effects 0.000 title abstract description 11
- 235000009200 high fat diet Nutrition 0.000 claims abstract description 16
- 235000021070 high sugar diet Nutrition 0.000 claims abstract description 8
- 206010067125 Liver injury Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000006041 probiotic Substances 0.000 abstract description 14
- 235000018291 probiotics Nutrition 0.000 abstract description 14
- 210000004185 liver Anatomy 0.000 abstract description 9
- 230000000529 probiotic effect Effects 0.000 abstract description 6
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 abstract description 3
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 abstract description 3
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 3
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 238000001179 sorption measurement Methods 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 230000004792 oxidative damage Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 17
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000004003 subcutaneous fat Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000000062 effect on obesity Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 210000003207 subcutaneous adipocyte Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940046892 lead acetate Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The application discloses lactobacillus plantarum P101 for relieving obesity and lead toxicity and application thereof, and belongs to the technical field of microorganisms. The lactobacillus plantarum P101 is separated from farmhouse-made pickled Chinese cabbage in Jian City of Jiangxi province, the preservation number is CCTCC M2021108, and the preservation place is China center for type culture Collection of Wuhan City. The lactobacillus plantarum P101 is a gram positive bacterium, has higher antioxidant activity and in-vivo and in-vitro lead adsorption characteristics, and can relieve liver oxidative damage caused by obesity and lead exposure to a certain extent. The lactobacillus plantarum P101 strain has good safety and probiotic performance, and plays a beneficial role in the application of relieving obesity caused by high-sugar and high-fat diet and relieving lead exposure toxicity.
Description
Technical Field
The application belongs to the technical field of microorganisms, and particularly relates to lactobacillus plantarum P101 for relieving obesity and lead toxicity and application thereof.
Background
With the increasing level of living, obesity has become a public health problem of worldwide concern, the pathological basis of which includes systemic low-grade chronic inflammation and lipid metabolism disorder, while the causes of which include sedentary, motionless and unhealthy lifestyle habits such as high-sugar high-fat diet, and the use of diet to induce obesity has become the most commonly used method in obesity research. Research shows that probiotics can regulate intestinal microbial homeostasis and influence biosynthesis and metabolism of various key molecules including short-chain fatty acid, thereby having certain treatment effect on obesity taking fat accumulation as a main phenotype.
Lead is a common heavy metal pollutant in life, and the main ways of entering human bodies include automobile exhaust, street dust, unqualified food packages and food chain transmission. The long-term lead exposure can induce nervous system and cardiovascular system disorder, inflammatory reaction, liver injury, etc., and can cause mental retardation for teenagers. Research shows that the probiotics can relieve oxidative stress injury caused by lead on one hand, and can adsorb lead ions in intestinal tracts of human bodies on the other hand, so that lead is promoted to be discharged out of the body along with excrement. Thus, it is possible to treat the biotoxicity caused by lead exposure with probiotics.
Lactobacillus plantarum is a class of gram-positive bacteria, most of which are facultative anaerobes, one of the accepted species of probiotics. Lactobacillus plantarum is closely related to human life and is widely found in nature, especially in various fermented foods such as vegetables, meat, dairy products and the like. Meanwhile, lactobacillus plantarum also exists in human gastrointestinal tracts as probiotics, adjusts the balance of intestinal microorganisms, controls toxin level in human bodies, enhances organism immunity, eliminates harmful substances, and has great significance on organism health.
Disclosure of Invention
The application aims to provide lactobacillus plantarum P101 (Lactobacillus Plantarum P101) for relieving obesity and lead toxicity and application thereof; the lactobacillus plantarum P101 has good probiotics and has high antioxidant activity and in-vivo and in-vitro lead adsorption characteristics.
The application relates to a lactobacillus plantarum P101 for relieving obesity and lead toxicity, wherein the lactobacillus plantarum P101 is stored in the China center for type culture Collection (university of Wuhan) of Wuhan in 2021, and the storage number is: cctccc M2021108.
Further, the lactobacillus plantarum P101 was isolated from farmhouse-made pickled Chinese cabbage.
The lactobacillus plantarum P101 can grow on an MRS agar plate culture medium, is gram-positive bacillus, is facultative anaerobic and does not produce spores. To maintain the excellent performance of the lactobacillus plantarum of the present application, it was stored in an MRS mixed preservation solution containing 25% glycerol and frozen at-80 ℃.
Another object of the application is to provide an application of lactobacillus plantarum P101 in preparing medicines, foods and health care products for relieving obesity.
Further, the obesity is obesity induced by a high-sugar high-fat diet.
Further, the viable count of Lactobacillus plantarum P101 used in the application is 10 8 ～10 9 CFU/mL。
The application also aims to provide application of lactobacillus plantarum P101 in preparing medicines, foods and health care products for relieving lead toxicity.
Further, the lead toxicity is biotoxicity caused by low concentration lead exposure.
Further, the viable count of Lactobacillus plantarum P101 used in the application is 10 8 ～10 9 CFU/mL。
The application takes lactobacillus separated and identified in traditional pickled Chinese cabbage as a research object, and intervenes and treats obesity and lead pollution model through animal experiments, so as to provide a new idea for the application of probiotics and the treatment of common public health problems.
The results of mice with the high-sugar and high-fat feed induced obesity model and the lead acetate solution induced chronic lead exposure model show that: lactobacillus plantarum P101 can effectively regulate lipid metabolism disorder induced by high-sugar and high-fat diet, remarkably increase lead discharge in mouse feces and reduce lead accumulation in viscera. The lactobacillus plantarum P101 is used as probiotics, is a strain with excellent performance and higher safety, and can effectively relieve diet-induced obesity and biotoxicity caused by lead exposure, so that the lactobacillus plantarum P101 has higher research value and application.
Compared with the prior art, the application has the beneficial effects that:
the lactobacillus plantarum P101 has remarkable treatment effect on obesity induced by high-sugar and high-fat diet, and can relieve liver injury caused by low-concentration lead exposure, so that the application field of the lactobacillus plantarum P101 is expanded, and the application value of the lactobacillus plantarum P101 is improved.
Drawings
Figure 1 is a graph of lactobacillus plantarum P101 alleviating diet-induced weight gain in obese experimental mice (significant differences, P <0.05, are shown between the different lower case letters).
Figure 2 is a graph of the subcutaneous and epididymal fat coefficients of lactobacillus plantarum P101 in diet-induced obese experimental mice (significant differences, P <0.05, are shown between the different lower case letters).
Figure 3 is a graph of lactobacillus plantarum P101 alleviating TC (total cholesterol), TG (total triglycerides) levels in the liver of diet-induced obese experimental mice (significant differences, P <0.05, are shown between the different lower case letters).
Figure 4 is a graph of lactobacillus plantarum P101 alleviating TC and TG levels in serum of diet-induced obese experimental mice (significant differences, P <0.05, are shown between the different lower case letters).
Fig. 5 is a subcutaneous adipose tissue pathological section analysis (400-fold) of lactobacillus plantarum P101 alleviating diet-induced obesity experimental mice.
FIG. 6 shows the lead content measurement of the feces, liver and intestinal tracts of the Lactobacillus plantarum P101 test mice for alleviating lead toxicity.
FIG. 7 is a liver histopathological section analysis (400-fold) of Lactobacillus plantarum P101 lead toxicity relieving experimental mice.
Detailed Description
In order to make the objects, technical solutions and advantages of the present application more apparent, the technical solutions of the present application will be clearly and completely described in the following examples. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1: alleviating obesity induced by high-sugar and high-fat diet
21 6 week old Kunming mice were acclimatized for 1 week and were randomized into three groups: the control group, the high-sugar and high-fat diet group and the probiotic treatment group are fed with daily maintenance feed every day, and the high-sugar and high-fat diet group and the probiotic treatment group are fed with high-sugar and high-fat feed, and all feeds and drinking water are freely ingested for 8 weeks. The control group and the high-sugar high-fat diet group were given 200. Mu.L of phosphate buffer per day as controls at weeks 7 and 8, and the probiotic-treated group was given 200. Mu.L per day (10) 8 CFU/mL) lactobacillus plantarum P101 bacterial suspension. Mice body weight was recorded daily during the experiment. Mice were euthanized 24h after the last dose, the neck was broken after ocular vein blood sampling, and liver, subcutaneous fat and epididymal fat were collected for subsequent physicochemical analysis. Liver and subcutaneous adipose tissues were embedded in paraffin and cut into 5 μm slices, stained with hematoxylin and eosin dyes, and examined under a microscope for histopathological morphology.
The results are shown in figure 1, where the high-sugar high-fat diet significantly increased the weight of mice, while the intervention of lactobacillus plantarum P101 significantly reduced the weight gain of mice.
As shown in fig. 2, the high-sugar high-fat diet significantly increased the subcutaneous and epididymal fat weights of mice, which were restored to normal levels by lactobacillus plantarum P101.
The results are shown in figure 3, where the high-sugar high-fat diet significantly increased TC, TG levels in the liver of mice, and the lactobacillus plantarum P101 treated group was reduced to normal levels.
The results are shown in figure 4, where the high-sugar high-fat diet significantly increased TC, TG levels in the serum of mice, and the lactobacillus plantarum P101 treated group was reduced to normal levels.
As a result, as shown in fig. 5, the subcutaneous adipocyte size of the high-sugar high-fat diet group was significantly increased, and the subcutaneous adipocyte size of the lactobacillus plantarum P101 treatment group was reduced to a normal level.
The results show that the lactobacillus plantarum P101 can relieve obesity symptoms caused by high-sugar and high-fat diet to a certain extent, including weight increase caused by reducing additional energy intake and total cholesterol and triglyceride content in serum and liver, and the lactobacillus plantarum can also relieve fat accumulation to a certain extent through the section observation of adipose tissues.
Example 2: alleviating biotoxicity caused by lead exposure
After 1 week of adaptation, 14 6 week old Kunming mice were randomized into two groups: lead exposure group and probiotic treatment group, the lead exposure group was free to drink 1g/L Pb 2+ The probiotic treatment group drinks 1g/L Pb 2+ Is infused with 200 mu L (10) 8 CFU/mL) for 2 weeks. Mice were euthanized 24h after the last dose, the ocular veins were bled and the neck was broken, and liver, colon and stool samples were collected for subsequent physicochemical analysis.
As shown in fig. 6, the lead content in the feces of the lactobacillus plantarum P101 treatment group was significantly increased, while the lead element content in the liver and colon was significantly decreased, indicating that the intervention of lactobacillus plantarum promoted lead excretion in the feces and thus reduced lead accumulation in the viscera.
As shown in fig. 7, the liver tissue section of the mice in the lead exposure group can obviously observe pathological symptoms such as cell cavitation, nuclear shrinkage, nuclear dissolution and the like, and the liver cell cavitation, necrosis and inflammatory infiltration caused by lead exposure can be relieved after the intervention treatment of lactobacillus plantarum P101, which indicates that the lactobacillus plantarum P101 has obvious treatment effect on the biotoxicity induced by lead exposure.
The results show that lactobacillus plantarum P101 can reduce lead accumulation in viscera by promoting lead excretion, and further relieve biotoxicity including liver injury and the like caused by lead exposure.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present application and not for limiting the same; while the application has been described in detail with reference to the preferred embodiments, those skilled in the art will appreciate that: modifications and equivalents of some of the features of the specific embodiments of the present application may be made, and they are all included in the scope of the present application as claimed.
Claims (2)
1. Application of lactobacillus plantarum P101 in preparing medicines for relieving obesity induced by high-sugar and high-fat diet;
the lactobacillus plantarum P101 is stored in the China center for type culture collection of Wuhan City in 2021, 1 month and 19 days, and the storage number is: cctccc M2021108.
2. Use of lactobacillus plantarum P101 as claimed in claim 1 in the manufacture of a medicament for alleviating liver damage caused by low concentration lead exposure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111431645.7A CN114164149B (en) | 2021-11-29 | 2021-11-29 | Lactobacillus plantarum P101 for relieving obesity and lead toxicity and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111431645.7A CN114164149B (en) | 2021-11-29 | 2021-11-29 | Lactobacillus plantarum P101 for relieving obesity and lead toxicity and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114164149A CN114164149A (en) | 2022-03-11 |
| CN114164149B true CN114164149B (en) | 2023-10-03 |
Family
ID=80481415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111431645.7A Active CN114164149B (en) | 2021-11-29 | 2021-11-29 | Lactobacillus plantarum P101 for relieving obesity and lead toxicity and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114164149B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114196593B (en) * | 2021-12-30 | 2023-07-28 | 南昌大学 | Lactobacillus plantarum P101 with high antioxidant activity and application thereof |
| CN115838650A (en) * | 2022-05-06 | 2023-03-24 | 佛山市孛特碧欧微生物科技有限公司 | Lactobacillus plantarum and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180040894A (en) * | 2016-10-13 | 2018-04-23 | 건국대학교 산학협력단 | Novel Lactobacillus plantarum Lb41 strain and compositions for the prevention and treatment of obesity containing the same |
| CN110684701A (en) * | 2019-11-19 | 2020-01-14 | 西南大学 | Lactobacillus plantarum S58 and application thereof in preparation of products for relieving obesity |
| AU2020101532A4 (en) * | 2020-07-28 | 2020-09-10 | Chongqing University Of Education | A Lactobacillus plantarum with the function of reducing weight and fat and an application thereof |
| CN112813003A (en) * | 2021-02-08 | 2021-05-18 | 青岛海华莱康生物医药技术有限公司 | Lactobacillus plantarum and application thereof in preparation of medicine or food for relieving diseases caused by hyperlipidemia |
| CN114292787A (en) * | 2021-12-31 | 2022-04-08 | 南昌大学 | Lactobacillus plantarum P101 for preventing liver and kidney injury and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102586148B (en) * | 2012-02-28 | 2013-05-08 | 江南大学 | Plant lactobacillus capable of relieving lead toxicity and application thereof |
| US10792317B2 (en) * | 2016-08-24 | 2020-10-06 | Synbio Tech Inc. | Method for reducing body fat by administering Lactobacillus plantarum |
-
2021
- 2021-11-29 CN CN202111431645.7A patent/CN114164149B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180040894A (en) * | 2016-10-13 | 2018-04-23 | 건국대학교 산학협력단 | Novel Lactobacillus plantarum Lb41 strain and compositions for the prevention and treatment of obesity containing the same |
| CN110684701A (en) * | 2019-11-19 | 2020-01-14 | 西南大学 | Lactobacillus plantarum S58 and application thereof in preparation of products for relieving obesity |
| AU2020101532A4 (en) * | 2020-07-28 | 2020-09-10 | Chongqing University Of Education | A Lactobacillus plantarum with the function of reducing weight and fat and an application thereof |
| CN112813003A (en) * | 2021-02-08 | 2021-05-18 | 青岛海华莱康生物医药技术有限公司 | Lactobacillus plantarum and application thereof in preparation of medicine or food for relieving diseases caused by hyperlipidemia |
| CN114292787A (en) * | 2021-12-31 | 2022-04-08 | 南昌大学 | Lactobacillus plantarum P101 for preventing liver and kidney injury and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 动物微生态制剂菌种的毒性试验;刘淑英;孟军;汪勇沛;巫从工;;上海畜牧兽医通讯(第02期);2-3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114164149A (en) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114164149B (en) | Lactobacillus plantarum P101 for relieving obesity and lead toxicity and application thereof | |
| CN113337430B (en) | Lactobacillus paracasei NSL0201 and application thereof | |
| CN109481476B (en) | Application of lactobacillus fermentum CQPC04 in preparing food or medicine for improving ulcerative colitis | |
| CN111743159B (en) | Compound microbial preparation and application thereof in relieving depression and constipation | |
| Kuo et al. | Long-term use of probiotic-containing yogurts is a safe way to prevent Helicobacter pylori: based on a Mongolian gerbil's model | |
| CN114292787B (en) | Lactobacillus plantarum P101 for preventing liver and kidney injury and application thereof | |
| CN114107121B (en) | Bacillus coagulans and application thereof in treatment of alcoholic liver disease | |
| WO2021143621A1 (en) | Anaerostipes sp b2131 strain and use thereof in inflammatory bowel diseases | |
| CN113913346A (en) | Lactobacillus paracasei JN-1 and application thereof | |
| Mu et al. | Lactobacillus plantarum KFY02 enhances the relieving effect of gardenoside on montmorillonite induced constipation in mice | |
| CN117327608A (en) | Lactobacillus rhamnosus strain and application thereof | |
| Lee et al. | Anti-obesity effect of vegetable juice fermented with lactic acid bacteria isolated from kimchi in C57BL/6J mice and human mesenchymal stem cells | |
| CN114134080A (en) | Bacillus coagulans and application thereof in treatment of colitis | |
| CN114344344B (en) | Application of lactobacillus reuteri in relieving obesity function of high-fat diet-induced mice and compound containing lactobacillus reuteri | |
| CN116731929A (en) | Lactobacillus mucilaginosus ZS40 and application thereof | |
| Yi et al. | Effects of Lactobacillus fermentum CQPC04 on lipid reduction in C57BL/6J mice | |
| Li et al. | Effect of Lactobacillus fermentum HFY06 combined with arabinoxylan on reducing lipid accumulation in mice fed with high-fat diet | |
| CN113717883A (en) | Lactobacillus plantarum FLPL05 capable of promoting body health and longevity and application thereof | |
| CN113088470A (en) | Lactobacillus rhamnosus L.rB16 and application thereof | |
| CN114854623B (en) | Lactobacillus delbrueckii subspecies bulgaricus, microbial inoculum containing lactobacillus delbrueckii subspecies bulgaricus and application of lactobacillus delbrueckii subspecies bulgaricus | |
| CN116919998A (en) | Application of lactobacillus plantarum SHY21-2 in preventing and treating pathogenic bacteria infection and enhancing immunity in aquaculture | |
| CN114533768B (en) | Application of lactobacillus probiotics CGMCC No.1.13855 in preparing medicament for treating diabetes | |
| CN116676240B (en) | Lactobacillus rhamnosus and application thereof in preventing or treating alcoholic liver disease | |
| CN110540951A (en) | Lactobacillus plantarum LP10 and application thereof | |
| CN116410898B (en) | Frozen Wittman's bacteria ELF131 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |